Approval · Notice of Compliance 16433 · 2014
FORXIGA: Notice of Compliance 16433
Issued December 12, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16433
- Date
- December 12, 2014
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Other blood glucose lowering drugs excluding insulins
Products in this notice
Medicinal ingredients
- DAPAGLIFLOZIN 10 MG per TAB
- DAPAGLIFLOZIN 5 MG per TAB